Peter Lawrence, Cardurion Pharmaceuticals CEO
July 16, 2024 07:45 AM EDTUpdated 11:05 AM
Financing
Startups

Bain-backed Car­du­ri­on rais­es $260M to fund ex-Imara drug, buy more car­dio as­sets

Kyle LaHucik

Senior Reporter

Car­du­ri­on Phar­ma­ceu­ti­cals is go­ing shop­ping for more car­dio drug can­di­dates.

The Burling­ton, MA-based biotech, which launched in 2017 with a

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times